Q.Can you list 10 recombinant proteins which are used in medical practice? Find out where they are used as therapeutics (use the internet).

Of course. This is a direct application of the biotechnology chapter. The NCERT textbook explicitly mentions that therapeutic products derived from recombinant DNA technology are now a major part of modern medicine. While the textbook lists a few key examples, you are expected to be aware of the broader set used in practice.

Here are 10 recombinant proteins used as therapeutics, along with their medical applications:

1. Insulin – Used to manage diabetes mellitus. This was the first recombinant therapeutic approved for human use.
2. Human Growth Hormone – Used to treat growth disorders in children, such as pituitary dwarfism.
3. Erythropoietin (EPO) – Used to treat anaemia, especially in patients with chronic kidney failure or those undergoing chemotherapy.
4. Factor VIII – Used to treat Haemophilia A, a blood clotting disorder.
5. Factor IX – Used to treat Haemophilia B.
6. Interferon-alpha – Used in the treatment of hepatitis B, hepatitis C, and certain cancers like leukaemia.
7. Interferon-beta – Used to manage multiple sclerosis.
8. Tissue Plasminogen Activator (tPA) – Used as a clot-dissolving agent in patients suffering from heart attacks or strokes.
9. Granulocyte Colony-Stimulating Factor (G-CSF) – Used to stimulate white blood cell production in patients undergoing chemotherapy or bone marrow transplants.
10. Hepatitis B Vaccine (surface antigen) – Used for immunisation against Hepatitis B virus infection.

Recombinant protein therapeutics represent one of the most transformative achievements of modern biotechnology. Before the 1980s, many essential human proteins could only be obtained from animal or human sources — insulin from pigs or cows, growth hormone from cadavers — which carried risks of contamination, allergic reactions, and limited supply. The breakthrough came when scientists learned to insert the human gene for a desired protein into a host organism (typically bacteria like E. coli or yeast, sometimes mammalian cells), causing it to produce the human protein in large quantities. This is the core idea of recombinant DNA technology: using a living factory to make a precise copy of a human therapeutic protein.

This chapter (Chapter 9, Biotechnology: Principles and Processes) covers the tools and process of recombinant DNA technology rather than a catalogue of therapeutic products, so the exercise itself invites you to research current examples (as its own "use the internet" instruction says). Compiled from general biotechnology/pharmacology knowledge, here are ten recombinant proteins used as therapeutics, along with their medical applications:

1. Recombinant Human Insulin — Used to treat diabetes mellitus (Type 1 and some Type 2 cases). It was the first recombinant therapeutic approved for human use (1982). The NCERT textbook specifically mentions its production in E. coli by inserting the human insulin gene.

2. Human Growth Hormone (Somatropin) — Used to treat growth hormone deficiency in children and adults, leading to short stature. Before recombinant technology, it was extracted from human pituitary glands, which risked transmitting Creutzfeldt-Jakob disease.

3. Erythropoietin (EPO) — Used to treat anaemia, especially in patients with chronic kidney disease or those undergoing chemotherapy. It stimulates red blood cell production. The NCERT textbook mentions this as an example of a recombinant therapeutic.

4. Factor VIII — Used to treat Haemophilia A, a bleeding disorder caused by deficiency of this clotting factor. Recombinant Factor VIII eliminated the risk of viral contamination (like HIV and hepatitis) from blood-derived products.

5. Factor IX — Used to treat Haemophilia B (Christmas disease). Like Factor VIII, recombinant production ensures safety and consistent supply.

6. Interferon-alpha — Used to treat certain viral infections (like hepatitis B and C) and some cancers (like hairy cell leukaemia and melanoma). Interferons are natural proteins that help the immune system fight viruses and tumours.

7. Interferon-beta — Used to treat multiple sclerosis, an autoimmune disease affecting the central nervous system. It reduces the frequency of relapses.

8. Tissue Plasminogen Activator (tPA) — Used as a "clot-buster" in acute myocardial infarction (heart attack) and ischaemic stroke. It dissolves blood clots by activating plasminogen. The NCERT textbook mentions this as a recombinant therapeutic.

9. Granulocyte Colony-Stimulating Factor (G-CSF) — Used to stimulate white blood cell production in patients undergoing chemotherapy or bone marrow transplantation, reducing the risk of infection.

10. Monoclonal Antibodies (e.g., Rituximab, Trastuzumab) — These are recombinant antibodies used to treat various cancers and autoimmune diseases. For example, Trastuzumab (Herceptin) targets HER2-positive breast cancer, and Rituximab targets CD20 on B cells in non-Hodgkin lymphoma. While not a single protein, they are a major class of recombinant therapeutics.

Alternative Approach: Group by the Medical Problem Solved, Not by Protein Name

Instead of listing recombinant proteins one by one, it helps to organise them by the

category of medical need they address -- this is a more memorable, exam-transferable

way to recall examples, and it also explains why each had to be made recombinant.

Step 1: Hormonal deficiencies -- insulin (diabetes) and human growth hormone

(pituitary dwarfism). Before recombinant technology, both came from animal/cadaver

sources with contamination and supply risk.

Step 2: Blood and clotting disorders -- Factor VIII (Haemophilia A), Factor IX

(Haemophilia B), and tissue plasminogen activator (clot-busting in heart attack/stroke).

Blood-derived versions of these historically carried viral contamination risk (HIV,

hepatitis) -- recombinant production removed that risk entirely.

Step 3: Blood-cell/immune support -- erythropoietin (stimulates red blood cell

production; used in anaemia/kidney failure) and G-CSF (stimulates white blood cells;

used after chemotherapy).

Step 4: Antiviral/anticancer signalling proteins -- interferon-alpha (hepatitis,

some cancers) and interferon-beta (multiple sclerosis).

Key Takeaway:

Grouping by "what problem is being solved" rather than memorising a flat list makes it

easy to generate more examples on demand: any protein that is (a) naturally present in

the human body in only tiny amounts, (b) needed in large therapeutic quantities, and (c)

too complex/costly/risky to purify from a natural source is a strong candidate for

recombinant production -- which is exactly the logic used to identify all ten proteins

above.